www.hqdrug.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Surgery
- Urinary Tract
- Women's Health
Generic Calcitriol - Rocaltrol
Generic Rocaltrol
Generic Rocaltrol is used for managing certain conditions caused by high or low parathyroid hormone levels. It is used to manage low blood calcium levels in patients who are on chronic kidney dialysis.
£ 1.05
Buy now!
Country, language and currency
- Testimonials
-
Hello , today i've received the package . All is ok . Thank You very much . I'm glad to work with You .
Read more »
-
- Calcitriol as Effective as Vitamin D Analogues, but Cheaper - Renal and Urology News
- Calcitriol as Effective as Vitamin D Analogues, but CheaperRenal and Urology NewsNATIONAL HARBOR, Md
- Rockwell Medical Reports First Quarter 2012 Results - MarketWatch (press release)
- Rockwell Medical Reports First Quarter 2012 ResultsMarketWatch (press release)Preparation for Calcitriol (vitamin-D) launch on track
- Rockwell Medical Completes Patient Enrollment in PRIME Clinical Study - MarketWatch (press release)
- Rockwell Medical Completes Patient Enrollment in PRIME Clinical StudyMarketWatch (press release)Rockwell's Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism addresses a $350M US market
- Rockwell Medical Completes Patient Enrollment in PRIME Clinical Study - Healthcare Global (press release)
- Rockwell Medical Completes Patient Enrollment in PRIME Clinical StudyHealthcare Global (press release)Rockwell's Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism addresses a $350M US market
- Foamix Obtains US Patent 'Waterless Hydrophilic Foam' for Dermatological and ... - Healthcare Global (press release)
- Foamix Obtains US Patent 'Waterless Hydrophilic Foam' for Dermatological and
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
